Moody National Bank Trust Division Cuts Stake in McKesson Corporation $MCK

Moody National Bank Trust Division lessened its stake in shares of McKesson Corporation (NYSE:MCK) by 30.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,344 shares of the company’s stock after selling 591 shares during the quarter. Moody National Bank Trust Division’s holdings in McKesson were worth $1,102,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of MCK. Brighton Jones LLC boosted its holdings in McKesson by 46.3% in the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock worth $1,438,000 after acquiring an additional 798 shares during the period. Caxton Associates LLP purchased a new stake in shares of McKesson during the first quarter valued at approximately $233,000. Sivia Capital Partners LLC raised its stake in shares of McKesson by 77.9% during the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock valued at $502,000 after purchasing an additional 300 shares during the period. American Century Companies Inc. raised its stake in shares of McKesson by 16.0% during the second quarter. American Century Companies Inc. now owns 13,718 shares of the company’s stock valued at $10,052,000 after purchasing an additional 1,895 shares during the period. Finally, Global Retirement Partners LLC acquired a new position in shares of McKesson during the second quarter worth $2,319,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares in the company, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,868 shares of company stock worth $3,743,820. Company insiders own 0.08% of the company’s stock.

McKesson Trading Down 0.3%

McKesson stock opened at $879.57 on Thursday. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00. The stock has a market cap of $107.74 billion, a P/E ratio of 25.30, a price-to-earnings-growth ratio of 1.42 and a beta of 0.38. The stock has a 50 day moving average of $906.79 and a 200-day moving average of $837.49.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The business’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s payout ratio is presently 9.43%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MCK shares. Leerink Partners restated an “outperform” rating and issued a $1,085.00 target price on shares of McKesson in a research note on Thursday, March 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $966.00 price target on shares of McKesson in a research note on Thursday, January 29th. JPMorgan Chase & Co. boosted their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Robert W. Baird set a $968.00 price objective on shares of McKesson in a research report on Wednesday, January 14th. Finally, Mizuho raised their target price on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research note on Thursday, February 5th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, McKesson presently has a consensus rating of “Moderate Buy” and a consensus target price of $960.93.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.